NCT00048074 - DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis | Biotech Hunter

Enrollment

1,395

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions

Post Menopausal Osteoporosis

Interventions

DRUG

ibandronate [Bonviva/Boniva]

2mg iv every 2 months

DRUG

ibandronate [Bonviva/Boniva]

2.5mg po daily

DRUG

ibandronate [Bonviva/Boniva]

3mg iv every 3 months

Trial Locations (64)

1036

Budapest

1180

Brussels

1399

Copenhagen

2010

Darlinghurst

2139

St Leonards

2750

Ballerup Municipality

3084

Melbourne

3129

Sydney

4010

Stavanger

4020

Liège

5507

Haugesund

6000

Nedlands

7100

Vejle

7129

Sommerset West

7500

Cape Town

8000

Aarhus

9000

Aalborg

10029

New York

11000

Mexico City

12200

Berlin

16011

Arenzano

19610

Wyomissing

20246

Hamburg

20817

Bethesda

23462

Virginia Beach

28046

Madrid

30501

Gainesville

34748

Leesburg

37067

Valeggio sul Mincio

39008

Santander

44789

Bochum

45000

Orléans

53100

Siena

53792

Madison

57701

Rapid City

58103

Fargo

58503

Bismarck

59120

Billings

63110

St Louis

64460

Monterrey

68131

Omaha

69437

Lyon

78229

San Antonio

83814

Coeur d'Alene

87106

Albuquerque

92270

Rancho Mirage

92618

Irvine

72205-7199

Little Rock

M5C 2T2

Toronto

H7T 2P5

Laval

H2X 3J4

Montreal

H3A 1A1

Montreal

S7K 0H6

Saskatoon

305 99

Pilsen

128 00

Prague

0176

Oslo

86-300

Grudziądz

30-510

Krakow

31-501

Krakow

Unknown

Pretoria

08003

Barcelona

AB25 1LD

Aberdeen

M13 9WL

Manchester

NE7 7DN

Newcastle upon Tyne

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY